Imaceva 400

Imatinib belongs to the class of medicines known as tyrosine kinase inhibitors. It is used in the treatment of blood cancer (chronic myeloid leukaemia and Acute lymphocytic leukemia) and gastrointestinal stromal tumor. Imatinib should be taken with food, but better to have it same time every day to get the most benefit. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include rash, vomiting, abdominal pain and diarrhea. Other than this, water retention and swelling are commonly observed side effects. Let your doctor know if you experience unexpected rapid weight gain. Your doctor may advice for regular monitoring of blood cells and liver function while you are taking this medicine. Do not drive or do anything requiring mental focus if you experience dizziness and blurry vision. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. Imatinib is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer.

• Blood cancer (Chronic myeloid leukaemia) • Blood cancer (Acute lymphocytic leukemia) • Gastrointestinal stromal tumour

Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML. Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.

Adult Dose: Acute Lymphoblastic Leukemia Indicated for adults with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) 600 mg PO qDay Myelodysplastic/Myeloproliferative Diseases Indicated in adults with myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene re-arrangements as determined with an FDA-approved test 400 mg PO qDay Hypereosinophilic Syndrome/Eosinophilic Leukemia Indicated for adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR-alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR-alpha fusion kinase negative or unknown 400 mg PO qDay In patients with demonstrated F1P1L1-PDGFR-alpha fusion kinase: 100 mg PO qDay; may increase to 400 mg qDay in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy Chronic Myeloid Leukemia Chronic phase Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase 400 mg PO qDay Chronic phase after failure of interferon-alpha therapy: May increase to 600 mg/day in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response Accelerated phase or blast crisis 600 mg PO qDay May increase to 400 mg PO q12hr in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response Dermatofibrosarcoma Protuberans Indicated for adults with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans 400 mg PO q12hr Mastocytosis Indicated for adults with aggressive systemic mastocytosis without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown Without D816V c-Kit mutation: 100 mg PO qDay c-Kit mutational status unknown: 400 mg PO qDay if not responding to other therapies ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR-alpha): 100 mg PO qDay initially, may increase to 400 mg/day in absence of adverse effects if response to therapy is insufficient Gastrointestinal Stromal Tumors Unresectable and/or metastatic malignant GIST 400 mg PO qDay; may increase to 400 mg BID in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions Adjuvant treatment following complete gross resection of GIST 400 mg PO qDay x3 years Hepatic impairment: Severe: Reduce dose by 25%. Child Dose: Chronic Myeloid Leukemia Indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase 1 year: 340 mg/m²/day PO; not to exceed 600 mg/day Acute Lymphoblastic Leukemia Indicated for treatment of newly diagnosed children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) 1 year: 340 mg/m²/day PO; not to exceed 600 mg/day

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Imatinib is to be taken with food.

If you miss a dose of Imatinib, skip it and continue with your normal schedule. Do not double the dose.

Common: • Abdominal pain • Diarrhea • Fatigue • Muscle cramp • Musculoskeletal (bone, muscle or joint) pain • Nausea • Rash • Vomiting

[UNSAFE] Imatinib may cause side effects which could affect your ability to drive. Always take it with food and a full glass of water to prevent nausea. It may cause dizziness or blurred vision. Do not drive or do anything requiring concentration until you know how it affects you. Water retention and swelling are very common side effects of Imatinib. Notify your doctor if you have unexpected rapid weight gain. Do not change the dose or discontinue use without consulting your doctor. Notify your doctor about all the medications you are taking, including over the counter medicines and dietary supplements. Your doctor may get regular blood tests done to monitor your liver function and the number of blood cells in your blood.

Hypersensitivity. Lactation.

Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.

[CONSULT YOUR DOCTOR] It is not known whether it is safe to consume alcohol with Imatinib. Please consult your doctor.

[CONSULT YOUR DOCTOR] Imatinib is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

[CONSULT YOUR DOCTOR] Imatinib is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. Lactating women should not breastfeed while using this drug and one month after stopping it.

[CAUTION] Imatinib should be used with caution in patients with kidney disease. Dose adjustment of Imatinib may be needed. Please consult your doctor. [CAUTION] Imatinib should be used with caution in patients with severe liver disease. Dose adjustment of Imatinib may be needed. Please consult your doctor.

She is suffering from chronic myeloid leukemia Hi Kindly consult to Ayurvedic doctor at your local city area , face to face consult is needed. Can blood cancer patients 1st stage do sex with normal girl Sir a blood cancer patients do sex with normal girl can any problem or cause doing with girl or side effect give suggestions Thanks Wait till blood cancer gets cured. Mh mother have blood cancer .recently she got her first induction chemotherapy.in CBC test Immature myeloid cells 18 percent what are indicate.is it serious .is it shown presence of cancer in blood old tell me Dear Mam Greetings from 1mg, The reports shows low hemoglobin and platelet count which can be due to chemotherapy. Is there anything related to blood cancer sir/madam?? For that we need to do bone marrow aspiration, flow cytometry.CBC suggestive of chronic Leukaemia soEven if it is Leukaemia, it will need not to be treated as it is asymptomatic in majority of times. Blood Cancer. Is there any medicine to cure blood cancer. Case has to be seen in person What is t-cell all ??? And treatment This is my mother first born mero report Now the blast is less then 5% after 1 month treatment This is blood cancerShe is in remission I seem to have lung cancer , becoz all the symptoms are same as lung cancer. I test my blood, they suggests me that it is highly probable to lung cancer. Sir what can i do now. This is in preliminary stage Do you think that lung cancer is diagnosed from blood please tell me the symptoms of blood cancer Blood cancer can have following symptoms Fever Bleeding Lymphadenopathy Patechia